Hugh J. McMillan

Hugh J. McMillan

Auto-generated profile, based on publicly available information

Hugh J. McMillan

Division of Neurology, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KSKevin A. Strauss
Kevin A. Strauss
MFMichelle Farrar
Michelle Farrar
FMFrancesco Muntoni
Francesco Muntoni
KSKayoko Saito
Kayoko Saito
JMJerry R. Mendell
Jerry R. Mendell
TMThomas A. Macek
Thomas A. Macek
SPR1NT (NCT03505099) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelicSMN1mutations treated at ≤6 weeks of life. Here, we report final results for 14 children with two copies ofSMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26;P < 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.

1 March 2021 in Journal of Hepatology
Verified
Journal Article
Open access
DCDeepa Chand
Deepa Chand
FMFranziska Mohr
Franziska Mohr
HMHugh McMillan
Hugh McMillan
FTFrancis Fonyuy Tukov
Francis Fonyuy Tukov
KMKyle Montgomery
Kyle Montgomery
GKGerd Kullak-Ublick
Gerd Kullak-Ublick
Spinal muscular atrophy (SMA) is an autosomal recessive, childhood-onset motor neuron disease. Onasemnogene abeparvovec (OA) is a gene therapy designed to address SMA's root cause. In pivotal mouse toxicology studies, the liver was identified as a major site of OA toxicity. Clinical data reflect elevations in serum aminotransferase concentrations, with some reports of serious acute liver injury. Prophylactic prednisolone mitigates these effects. Herein, we aim to provide pragmatic, supportive guidance for identification, management, and risk mitigation of potential drug-induced liver injury. Data from 325 patients with SMA who had received OA through 31 December 2019, in 5 clinical trials, a managed access program (MAP), and a long-term registry (RESTORE), and through commercial use, were analyzed. Liver-related adverse events, laboratory data, concomitant medications, and prednisolone use were analyzed. Based on adverse events and laboratory data, 90 of 100 patients had elevated liver function test results (alanine aminotransferase, and/or aspartate aminotransferase, and/or bilirubin concentrations). Of these, liver-associated adverse events were reported for 34 of 100 (34%) and 10 of 43 (23%) patients in clinical trials and MAP/RESTORE, respectively. Two patients in MAP had serious acute liver injury, which resolved completely. While all events in the overall population resolved, prednisolone treatment duration varied (range: 33-229 days), with a majority receiving prednisolone for 60-120 days. More than 60% had elevations in either alanine aminotransferase, aspartate aminotransferase, or bilirubin concentrations prior to dosing. Greater than 40% received potentially hepatotoxic concomitant medications. Hepatotoxicity is a known risk associated with OA use. Practitioners should identify contributing factors and mitigate risk through appropriate monitoring and intervention. Onasemnogene abeparvovec is a type of medicine called a "gene therapy," which is used to treat babies and young children who have a rare, serious inherited condition called "spinal muscular atrophy" (SMA). It works by supplying a fully functioning copy of the survival motor neuron or SMN gene, which then helps the body produce enough SMN protein. However, it can cause an immune response that could lead to an increase in enzymes produced by the liver. This article provides information about the liver injury and how to prevent and recognize if it happens, so that it may be treated properly.

17 June 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KSKevin A. Strauss
Kevin A. Strauss
MFMichelle Farrar
Michelle Farrar
FMFrancesco Muntoni
Francesco Muntoni
KSKayoko Saito
Kayoko Saito
JMJerry R. Mendell
Jerry R. Mendell
TMThomas A. Macek
Thomas A. Macek
Most children with biallelicSMN1deletions and threeSMN2copies develop spinal muscular atrophy (SMA) type 2. SPR1NT (NCT03505099), a Phase III, multicenter, single-arm trial, investigated the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelicSMN1mutations treated within six postnatal weeks. Of 15 children with threeSMN2copies treated before symptom onset, all stood independently before 24 months (P < 0.0001; 14 within normal developmental window), and 14 walked independently (P < 0.0001; 11 within normal developmental window). All survived without permanent ventilation at 14 months; ten (67%) maintained body weight (≥3rd WHO percentile) without feeding support through 24 months; and none required nutritional or respiratory support. No serious adverse events were considered treatment-related by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.

23 December 2016 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
CCCraig Campbell
Craig Campbell
HMHugh J. McMillan
Hugh J. McMillan
JMJean K. Mah
Jean K. Mah
MTMark Tarnopolsky
Mark Tarnopolsky
KSKathryn Selby
Kathryn Selby
KAKenneth M. Attie
Kenneth M. Attie

21 October 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RSRyan D. Schubert
Ryan D. Schubert
IHIsobel A. Hawes
Isobel A. Hawes
PRPrashanth S. Ramachandran
Prashanth S. Ramachandran
ARAkshaya Ramesh
Akshaya Ramesh
ECEmily D. Crawford
Emily D. Crawford
MWMichael Wilson
Michael Wilson

26 July 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
MDMarc-Olivier Deguise
Marc-Olivier Deguise
GBGiovanni Baranello
Giovanni Baranello
CMChiara Mastella
Chiara Mastella
ABAriane Beauvais
Ariane Beauvais
JMJean Michaud
Jean Michaud
RKRashmi Kothary
Rashmi Kothary
Objective: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra‐neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease.Methods: We analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA.Results: We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/‐ mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non‐alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation.Interpretation: This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.